We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Adria Calatayud
Roche Holding said Friday that it has received approval from the U.S. Food and Drug Administration for Columvi, a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The Swiss pharmaceutical giant said it obtained an accelerated approval based on data from an early-stage Phase 1 and 2 study, and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.
In the Phase 1 and 2 study, the drug showed a 56% overall response rate and a median duration of response of more than 18 months, the company said.
Roche said Columvi will be available in the U.S. in the coming weeks.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
June 16, 2023 01:29 ET (05:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
